Axsome Therapeutics, Inc. (LON:0HKF)

London flag London · Delayed Price · Currency is GBP · Price in USD
104.17
-0.74 (-0.71%)
At close: Jul 2, 2025
24.94%
Market Cap 4.03B
Revenue (ttm) 334.49M
Net Income (ttm) -215.38M
Shares Out n/a
EPS (ttm) -4.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 508
Average Volume 402
Open 102.97
Previous Close 104.92
Day's Range 102.97 - 104.19
52-Week Range 73.05 - 141.00
Beta n/a
RSI 64.77
Earnings Date Aug 4, 2025

About Axsome Therapeutics

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 ago... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2012
Employees 683
Stock Exchange London Stock Exchange
Ticker Symbol 0HKF
Full Company Profile

Financial Performance

In 2024, Axsome Therapeutics's revenue was $385.69 million, an increase of 42.53% compared to the previous year's $270.60 million. Losses were -$287.22 million, 20.1% more than in 2023.

Financial numbers in USD Financial Statements

News

Axsome Therapeutics Champions Brain Health During Alzheimer’s & Brain Awareness Month

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is ...

21 days ago - Financial Post

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is...

21 days ago - GlobeNewsWire

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...

4 weeks ago - GlobeNewsWire

Axsome initiated with an Outperform at Oppenheimer on revenue boost

Axsome Therapeutics (AXSM) is set for growth with Auvelity, initiated at Outperform. Read more here.

5 weeks ago - Seeking Alpha

Axsome Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ann...

6 weeks ago - GlobeNewsWire

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, ...

6 weeks ago - GlobeNewsWire

Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone

Previous term loan facility retired NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervo...

2 months ago - GlobeNewsWire

Axsome targets FDA decision on AXS-14 for fibromyalgia in Q2 2025

Axsome Therapeutics reports 62% YoY revenue growth in Q1 2025, fueled by Auvelity & Sunosi. Key milestones include Symbravo launch & AXS-14 FDA decision.

2 months ago - Seeking Alpha

Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ETCompany ParticipantsDarren Opland - Director, Corporate...

2 months ago - Seeking Alpha

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1

Axsome Therapeutics Inc (NASDAQ: AXSM) on Monday reported first-quarter 2025 revenues of $121.5 million, up from $75 million a year ago, beating the consensus of $119.87 million. Auvelity (oral antid...

2 months ago - Benzinga

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1

Axsome Therapeutics Inc  AXSM on Monday reported first-quarter 2025 revenues of $121.5 million, up from $75 million a year ago, beating the consensus of $119.87 million.

2 months ago - Benzinga

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Total 1Q 2025 net product revenue of $121.5 million, representing 62% year-over-year growth AUVELITY ® 1Q 2025 net product sales of $96.2 million, representing 80% year-over-year growth SUNOSI ® 1Q 20...

2 months ago - GlobeNewsWire

Earnings Scheduled For May 5, 2025

Companies Reporting Before The Bell • Recursion Pharmaceuticals (NASDAQ: RXRX) is likely to report quarterly loss at $0.52 per share on revenue of $18.08 million. • Freshpet (NASDAQ: FRPT) is estima...

2 months ago - Benzinga

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ann...

2 months ago - GlobeNewsWire

Axsome Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today a...

2 months ago - GlobeNewsWire

Kuehn Law Encourages Investors of Five Below, Inc. to Contact Law Firm

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Five Below, Inc. (NASDAQ: FIVE) breached the...

3 months ago - GlobeNewsWire

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) ...

3 months ago - GlobeNewsWire

Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) bre...

3 months ago - GlobeNewsWire

Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today a...

3 months ago - GlobeNewsWire

This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page ....

3 months ago - Benzinga